HAWKEYE BIO
Earlier diagnosis. Higher survival rates. Hawkeye is a new medical technology company focused on lung cancer.
CALIFORNIA, USA
More about Hawkeye Bio
NJF Capital presents Hawkeye Bio.
Lung cancer is the leading cause of cancer deaths worldwide, it usually starts growing very deep in the lung and without symptoms. Lung cancer is diagnosed late as the current screening method underperforms compared to other major cancers.
Hawkeye is the solution for identifying lung cancer patients earlier. Exhaled breath condensate method of Hawkeye has high specificity of 99.3% and sensitivity of 97.2%, is pain-free, 100% safe and cost-effective at any scale. Hawkeye has completed initial clinical validation with excellent performance and is expanding clinical validations in US, Europe and China in support of local regulatory approval and commercialization.
With Hawkeye, there will be a day in the near future when lung cancer can be detected so early that the five-year-survival rate increases to nearly 100%.